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This study evaluated the cellular immune response against Brucella species cytoplasmic
protein (CP) in peripheral blood mononuclear cells (PBMC) of 25 patients with brucellosis.
In vitro proliferation and cytokine gene expression and production were investigated. PBMC
from 14 patients proliferated in response to CP (responder patients [RPs]) and cells from 11
patients did not (nonresponder patients [NRPs]). CP-specific interleukin (IL)–2 and interferon-
g were significantly induced in PBMC from RPs, compared with cells from NRPs. No sig-
nificant differences were found in the production of IL-10 between the 2 groups. CP did not
induce IL-4 production. A close relationship was observed between the clinical status of the
patients and the T cell response against CP. Patient with acute infections responded to CP
and induced production of T helper 1 (Th1) cytokines, whereas chronically infected patients
did not. Diminished production of Th1 cytokines may contribute to T cell unresponsiveness
in chronic human brucellosis.
Brucella species are gram-negative facultative intracellular
bacteria that cause severe disease in both animals and humans.
Brucellosis remains endemic in many developing countries,
where it undermines animal health and productivity, causing
important economic losses [1]. It also has a high human toll
[2]. Brucella species often invade cells of the reticuloendothelial
system and can be sequestered in infected macrophages at spe-
cific locations within the body (e.g., spleen, brain, heart, liver,
and bone marrow) [3]. Among Brucella species, B. melitensis,
B. abortus, B. canis, and B. suis are pathogenic for humans.
After infection, most patients enter an acute phase with un-
dulant fever that can progress either to recovery or to chronicity.
Received 6 December 2001; revised 27 February 2002; electronically pub-
lished 17 June 2002.
Presented in part: 35th annual meeting of the Argentine Society of Im-
munology, Mar del Plata, Argentina (abstract 111; Medicina 2000; 60:759).
All subjects gave informed consent. Human experimentation guidelines
of the US Department of Health and Human Services were followed.
Financial support: Agencia Nacional de Promocio´n Cientı´fica y Tecno-
lo´gica, Argentina (PICT 05-06324 to C.A.F.; M.V.D. is a fellow); Consejo
Nacional de Investigaciones Cientı´ficas y Te´cnicas, Argentina (PEI 0358 to
G.H.G.; C.A.V. is a fellow; G.H.G., P.C.B., and C.A.F are research career
members).
Reprints or correspondence: Dr. Guillermo H. Giambartolomei, Uni-
versidad de Buenos Aires, Instituto de Estudios de la Inmunidad Humoral,
Facultad de Farmacia y Bioquı´mica, Junı´n 956, 4th Piso, Buenos Aires
1113, Argentina (ggiambart@ffyb.uba.ar).
The Journal of Infectious Diseases 2002;186:252–9
q 2002 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2002/18602-0015$15.00
Chronic disease is characterized by mild fever, focal manifes-
tations of the disease, and chronic fatigue syndrome.
Infection with Brucella species results in the activation of
cell-mediated immune responses [4, 5]. In mice, passive transfer
of immune cells indicates that protection against B. abortus
infection is mediated by CD41 and CD81 T cells [5–7], although
antibodies directed against the O chain of lipopolysaccharide
(LPS) [5, 6] or against outer membrane proteins [8] appear to
enhance resistance to infection, at least in certain host species.
The role of cytokines in mediating resistance to B. abortus in-
fection was underscored in the mouse model. The importance
of interleukin (IL)–12 in inducing a Th1-type response mod-
ulated by interferon (IFN)–g [9, 10] has been demonstrated.
Endogenous IL-10 could also play a role by down-regulating
protective immunity during B. abortus infection [11].
Although there is substantial information about the role of
cytokines and T cells in murine brucellosis, knowledge of cell-
mediated immune responses in humans is scarce [12, 13]. Most
studies of T cell responses in brucellosis have used heat-killed
whole bacteria or partially purified proteinaceous mixtures as
antigens [9, 10, 12, 14, 15]. Because these preparations are often
contaminated with bacterial LPS and DNA, the results derived
from experiments conducted to evaluate antigen-specific re-
sponsiveness could be masked by the cellular responses elicited
by these powerful stimulants [16].
The main goal of our laboratory has been to characterize
proteinaceous antigens from Brucella organisms. We have ob-
tained a preparation of cytoplasmic protein (CP; formerly LPS-
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used as antigen in an indirect ELISA to test the reactivity of
serum from different hosts. We found serum reactivity to CP in
humans with brucellosis and in cows, sheep, goats, pigs, and
dogs infected with different Brucella species [18–20], suggesting
that many internal antigens are common to all Brucella species.
We also have demonstrated that an 18-kDa Brucella cytoplasmic
protein, which is present in all Brucella species [21], can be used
for the serologic diagnosis of human and animal brucellosis [21,
22]. Functional studies have demonstrated that the 18-kDa an-
tigen is an enzyme with lumazine synthase activity [23].
In the present study, we evaluated the cellular immune re-
sponse against cytoplasmic proteins from Brucella organisms
in peripheral blood mononuclear cells (PBMC) from patients
with brucellosis. For this purpose, we used CP and recombinant
Brucella lumazine synthase (rBLS) as model stimulants. The
results are discussed in terms of the relevance of the cellular
immune response against Brucella proteins during infection.
Patients, Materials, and Methods
Study population. This study population comprised 25 con-
secutive patients (18 men and 7 women) with active brucellosis who
attended the Section of Brucellosis of the Hospital F. J. Mun˜iz
(Buenos Aires). Control subjects were 20 healthy persons (11 men
and 9 women) with no history of Brucella infection. The ages of
the patients and control subjects, respectively, were 14–59 years
( , years) and 23–45 years ( ,mean5 SD 42.25 12.9 mean5 SD
years). Brucellosis was diagnosed on the basis of clin-31.255 7.13
ical, serologic, bacteriologic, and epidemiologic data. Disease ac-
tivity was defined by the presence of typical signs and symptoms
(e.g., fever, splenomegaly, lymphadenopathy, myalgia, arthralgia,
and hepatic involvement). All patients but 1 showed positive results
in classic serologic tests, including standard tube agglutination, 2-
mercaptoethanol, Rose-Bengal, complement fixation, and Huddle-
son tests. In addition, we used ELISA to detect IgG antibodies to
Brucella CP (see below). In positive blood cultures from 6 patients,
we isolated B. abortus ( ) and B. melitensis and B. canis (1np 4
each). Because classic serologic tests use smooth Brucella species
as antigen, the patient from which B. canis (rough species) was
isolated was the one whose classic serologic results were negative,
as expected. Therapy with antimicrobials was initiated as soon as
the diagnosis of brucellosis was established. The initial treatment
was oral doxycycline (100 mg every 12 h for 42 days) plus parenteral
streptomycin (1.0 g every 24 h for 21 days).
Antigens and mitogens. CP was prepared by immunoadsorp-
tion of the DNAse/RNAse-treated cytoplasmic fraction of B. abor-
tus, as described elsewhere [17]. rBLS, obtained as described else-
where [23], contained !0.05 endotoxin units per 100 mg of protein,
as assessed by limulus amebocyte lysate analysis kit (Sigma Chem-
ical). Mycobacterial purified protein derivative (PPD; obtained
from the Instituto Nacional de Microbiologı´a Dr. Carlos Malbran,
Buenos Aires) and phytohemagglutinin (PHA; Sigma) were used
in parallel control cultures. The protein concentration was deter-
mined by protein assay (Bio-Rad Laboratories). Final concentra-
tions used in culture were 10 mg/mL for CP, PPD, and PHA and
5 mg/mL for rBLS. These concentrations were found previously to
provide optimal stimulation for proliferation and cytokine pro-
duction by human PBMC in our laboratory.
Isolation of PBMC. Cells were isolated from preservative-free
heparinized blood, as described elsewhere [24], and cultured at
PBMC/mL in RPMI 1640 medium supplemented with 25623 10
mM HEPES buffer, 2 mM L-glutamine, 10% heat inactivated hu-
man AB serum (Sigma), 100 U/mL penicillin, 100 mg/mL strep-
tomycin, and 0.25 mg/mL fungizone (complete medium). Viability
of cells, as determined by trypan blue exclusion, was always 195%.
In vitro blastogenesis. Blastogenesis assays were performed in
triplicate in round- or flat-bottom microtiter plates for antigen and
mitogen cultures, respectively (Costar). To each well, we added 100
mL of stimulant and 100 mL of cell suspension ( PBMC).523 10
Control cultures consisting of complete medium and cells were run
simultaneously. Cultures were incubated at 377C in a humidified
atmosphere (5% CO2 and 95% air) for 4 (PHA) or 6 (antigens)
days. At 18 h before harvest, we added 1.0 mCi of [3H]thymidine
(ICN Pharmaceuticals) in 25 mL of complete medium to each well.
Cells were harvested onto glass-fiber mats, washed with distilled
water with a harvester (Skatron Instruments), and dried overnight
at room temperature. The dried filters were placed in 3 mL of
scintillation fluid, and radioactive incorporation was measured by
liquid scintillation counter (Beckman Instruments). Results are ex-
pressed as stimulation indices (SIs) as follows: counts per minute
of stimulated per minute of unstimulated cultures.cultures/counts
SIs 12 were considered to be a specific response.
Stimulation of cytokine production. PBMC ( cells) were623 10
cultured in round-bottom polypropylene tubes (Sarstedt) in the
presence of RPMI 1640 medium supplemented with 25 mM HE-
PES buffer, 2 mM L-glutamine, 10% heat-inactivated fetal bovine
serum (Gibco BRL Life technologies), 100 U/mL penicillin, 100
mg/mL streptomycin, and 0.25 mg/mL fungizone (RPMI 1640 me-
dium), CP, rBLS, PPD, or PHA in a 1-mL volume. Cultures were
incubated at 377C in a humidified atmosphere (5% CO2) for 24 h
(RNA expression) or 48 h (cytokine secretion) in different tubes.
At the end of the incubation, cells were centrifuged (400 g at 47C)
and processed immediately for RNA extraction, whereas super-
natants were aliquoted and stored at 2707C until assayed for cy-
tokine production.
Detection of cytokine mRNA by semiquantitative reverse-tran-
scriptase polymerase chain reaction (RT-PCR). RT-PCR for cy-
tokine gene expression was done as described elsewhere [24]. Re-
sults are shown as fold increase over the mRNA levels of cells
cultured in the absence of antigen. Fold increases 12 were consid-
ered to be an up-regulation of the investigated cytokine gene.
Cytokine ELISAs. IL-4, IL-10, and IFN-g in culture super-
natants were measured by sandwich ELISA by use of paired cy-
tokine-specific monoclonal antibodies, according to the manufac-
turer’s instructions (BD PharMingen).
CP ELISA. Serum IgG reactivities against CP were assayed
by indirect ELISA, as described elsewhere [25]. Serum titer was
established as the reciprocal of the last serum dilution yielding an
optical density higher than the cutoff. Serum titers 1100 were con-
sidered to be a specific response.
Statistical analysis. Cytokine secretion and increase in mRNA
levels were compared by the nonparametric Mann-Whitney U test
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Figure 1. In vitro proliferation of peripheral blood mononuclear cells (PBMC) from patients with brucellosis. PBMC ( /well) from patients523 10
and healthy control subjects were stimulated with Brucella cytoplasmic proteins (10 mg/mL; A), recombinant Brucella lumazine synthase (5 mg/
mL; B), purified protein derivative (10 mg/mL; C), and phytohemagglutinin (5 mg/mL; D). Results are shown as stimulation indices (SIs) and were
calculated as follows: cpm of stimulated of unstimulated cultures. Each symbol represents the SI of PBMC of 1 subject.cultures/cpm
Results
rBLS- and CP-specific blastogenic response of patients with
brucellosis. We assessed the in vitro cellular immune response
against Brucella CP. CP induced T cell proliferation in PBMC
from 14 of 25 patients with brucellosis (SI, 12; figure 1A). In
contrast, cells from only 2 of 25 patients proliferated in response
to rBLS (figure 1B). PBMC from healthy control subjects
showed no response to CP and rBLS (SI, !2; figure 1A and
1B). The differences in proliferative responses were not due to
differences in background responses, since the unstimulated
(control) cultures did not differ significantly among the 3 groups
(data not shown). PBMC from all subjects proliferated in re-
sponse to the nonbrucellar antigen PPD and to the mitogen
PHA, with no significant difference observed among the groups
(figure 1C and 1D). Therefore, for further analysis, patients
with brucellosis were grouped according to the ability of their
PBMC to proliferate in vitro to CP. Fourteen patients were
classified as responder patients (RPs; SI, 12), and 11 patients
were classified as nonresponder patients (NRPs; SI, !2).
Expression of cytokine mRNA in CP-stimulated PBMC from
Brucella-infected patients. To determine whether the differ-
ences in cellular responsiveness between RPs and NRPs were
related to differences in cytokines profiles, we studied IL-2,
IFN-g, IL-4, and IL-10 mRNA expression. These cytokines
were chosen because they regulate T cell responses in vitro [26].
CP induced a significant ( ) up-regulation of IFN-g andP ! .001
IL-2 transcripts (geometric mean fold increase [GMFI], 5.55
and 4.31, respectively) in cells from RPs, compared with PBMC
from NRPs (GMFI, 1.22 and 0.92, respectively; figure 2A and
2B). No significant differences were found in the expression of
the IL-10 gene between the 2 patient groups. IL-10 mRNA
expression was induced in cells from 3 of 14 of the RPs (GMFI,
1.32) and in 2 of 11 NRPs (GMFI, 1.30; figure 2C). PBMC
from RPs and NRPs did not induce IL-4 gene transcription
(GMFI, 1.0; figure 2D). CP did not induce cytokine transcrip-
tion in PBMC from healthy control subjects (figure 2). Cytokine
gene transcription in response to PHA was detected in cells
from all subjects. There was no significant difference among
the 3 groups (data not shown). These results suggest the in-
duction of a Th1 response in RPs.
Cytokine production in PBMC culture supernatants. As at
the mRNA level, CP stimulation significantly increased (P !
) the secretion of IFN-g in PBMC from RPs, whereas no.0001
detectable levels of this cytokine were measured in culture su-
pernatants from NRPs. No differences in the CP-specific pro-
duction of IL-10 were found between PBMC from RPs and
NRPs. Under the same culture conditions, cells from RPs and
NRPs did not secrete IL-4 (figure 3A, 3B, and 3C).
CP-stimulated PBMC from healthy control subjects did not
produce detectable levels of the cytokines investigated. Cells
from all subjects produced IL-4, IL-10, and IFN-g in response






/jid/article-abstract/186/2/252/835495 by guest on 23 August 2019
JID 2002;186 (15 July) T Cell Unresponsiveness in Chronic Brucellosis 255
Figure 2. Brucella cytoplasmic proteins (CP)–induced cytokine mRNA expression in peripheral blood mononuclear cells (PBMC) from patients
with brucellosis. PBMC ( /mL) from responder patients (RPs), nonresponder patients (NRPs), and healthy control subjects (HCs) were623 10
stimulated with CP (10 mg/mL) for 24 h. The induced mRNA levels of interferon-g (A), interleukin (IL)–2 (B), IL-10 (C), and IL-4 (D) were
determined by reverse-transcriptase polymerase chain reaction. Responses are shown as fold increase over unstimulated PBMC. Each symbol
represents the PBMC response of 1 person. Horizontal lines, geometric means. All values were normalized with respect to glyceraldehyde-3-
phosphate dehydrogenase mRNA levels.
no significant differences among the 3 groups (figure 3A , 3B,
and 3C).
Anti-CP humoral responses in Brucella-infected patients. To
investigate the humoral immune response elicited against Bru-
cella proteins, CP-specific IgG antibodies were detected by in-
direct ELISA in serum samples from infected subjects and
healthy control subjects. High titers of CP-specific IgG anti-
bodies (titers >800) were detected in serum samples of 12 of
25 patients. In contrast, the remaining 13 patients developed a
marginal IgG response (titers<200) against Brucella CP (figure
4A). Moreover, the 4 patients who had no IgG anti-CP were
also negative for IgM-specific antibodies (data not shown).
Healthy control subjects did not produce anti-CP antibodies.
Because both antibody and T cell responses to CP were di-
chotomic in patients with brucellosis, we decided to further
investigate the relationship between humoral and cellular re-
sponses. Therefore, we compared the anti-CP IgG titer and SI
of CP-stimulated PBMC in infected patients. No correlation
( ) was found between the CP-specific humoral and2r p 0.014
cellular responses. Although some patients with a high SI had
low antibody titers, others developed strong humoral responses
with no cellular proliferation (figure 4B).
Correlation between Th1 responses and clinical status of pa-
tients with brucellosis. To learn which factors were possibly
associated with the lack of cellular proliferation and Th1-type
cytokine production in response to CP in NRPs, we compared
some parameters between the RP and NRP groups. We found
no significant differences between the groups for mean age or
sex. Antibiotic regimens were distributed evenly among groups.
Other factors that could potentially influence the immune re-
sponse did not seem to be associated with the dichotomy of
CP-specific cellular responses. No patient had an intercurrent
disease or a clinical condition that could affect the immune
response. In addition, no patient was taking immunosuppres-
sive agents or any drug known to modify leukocyte counts.
The mRNA levels of the costimulatory molecules CD80, CD86,
and CD40 ligand and the immunomodulatory cytokines IL-18
and transforming growth factor (TGF)–b were not significantly
different in CP-stimulated PBMC from RPs and NRPs (data
not shown).
Retrospective analysis of clinical records allowed us to re-
group the patients by acute or chronic disease duration, as
defined by Young [27]. We classified 13 patients as having acute
disease (duration of illness, 28–300 days; median, 60 days) and
12 with chronic disease (duration of illness, 400–1200 days;
median, 675 days). Of interest, the majority of RPs (9 of 14)
were in the acute category, whereas most NRPs (7 of 11) were
in the chronic category, although the difference was not statis-
tically significant. In agreement with this trend, the expression
of the IFN-g and IL-2 genes, which is closely associated with
the blastogenic response, was significantly up-regulated (P !
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Figure 3. Brucella cytoplasmic proteins (CP)–induced cytokine pro-
duction in peripheral blood mononuclear cells (PBMC) from patients
with brucellosis. PBMC ( /mL) from responder patients (v),623 10
nonresponder patients (V) and healthy control subjects (M) were stim-
ulated with RPMI 1640 medium, CP (10 mg/mL), purified protein de-
rivative (PPD; 10 mg/mL), and phytohemagglutinin (PHA; 5 mg/mL)
for 48 h. Interferon-g (A), interleukin (IL)–10 (B), and IL-4 (C) in the
supernatant was determined by antibody capture ELISA. Each symbol
(the mean of duplicate determinations) represents the concentration of
cytokine in the culture supernatant of PBMC of 1 person.
Figure 4. A, Antibody IgG titers to Brucella cytoplasmic proteins
(CP) in patients with brucellosis and control subjects. Serum IgG reac-
tivities against CP were assayed by indirect ELISA. Each symbol rep-
resents a serum sample from 1 subject. B, Comparison of cellular (stim-
ulation index [SI], X-axis) vs. humoral (IgG titer, Y-axis) responses in
patients with brucellosis.
and 2.97, respectively), compared with cells from patients with
chronic disease (GMFI, 1.68 and 1.60, respectively; figure 5A
and 5B). No differences were found in IL-4 and IL-10 expres-
sion between PBMC from patients with either acute or chronic
disease (figure 5C and 5D). Similar results were obtained when
IFN-g production in culture supernatants was evaluated (data
not shown). Thus, these results show that the CP-specific T cell
cytokine patterns observed in patients with brucellosis differ
between the acute and chronic phases of the disease. They also
suggest that diminished production of Th1 cytokines may con-
tribute to the T cell unresponsiveness to Brucella CP observed
in chronic human brucellosis.
Discussion
Brucella species usually replicate within reticuloendothelial
cells, and immunity depends on a suitable cell-mediated response
by the host [5, 6]. This response relies on the expression of bac-
terial proteinaceous antigens, in association with molecules of
the major histocompatibility complex, for recognition of the in-
fected cell by different T cell subsets. Because the T cell receptor
recognizes proteolitic fragments, it is not necessary for T cell
antigens to be exposed on the surface of intact bacteria and,
therefore, Brucella cytoplasmic proteins could also stimulate T
lymphocytes. This prompted us to investigate the cellular immune
response against Brucella cytoplasmic antigens in humans with
brucellosis.
Our results suggest a close relationship between a patient’s
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Figure 5. Brucella cytoplasmic proteins (CP)–specific cytokine mRNA levels in patients with acute and chronic brucellosis. Peripheral blood
mononuclear cells (PBMC) ( /mL) from healthy control subjects and patients with acute and chronic brucellosis were stimulated with CP (10623 10
mg/mL) for 24 h. The induced mRNA levels of interferon-g (A), interleukin (IL)–2 (B), IL-10 (C), and IL-4 (D) were determined by reverse-
transcriptase polymerase chain reaction. Responses are shown as fold increase over unstimulated PBMC. Each symbol represents the response of
PBMC of 1 person. Lines, geometric means. All values were normalized with respect to glyceraldehyde-3-phosphate dehydrogenase mRNA levels.
gens from Brucella. PBMC from patients with acute brucellosis
responded to CP and induced the production of Th1 cytokines,
whereas lymphocytes from patients with the chronic form of the
disease did not. Polarization of cellular immune responses have
been similarly observed in infectious diseases caused by parasites,
such as filariasis [28] and Chagas’ disease [29], and by intracellular
bacteria that cause leprosy [30, 31] and tuberculosis [32], where
distinct T cell cytokine profiles appear to control the clinical and
immunologic spectrum of the diseases.
Several mechanisms could account for the decreased Th1
response toward Brucella cytoplasmic antigens in patients with
chronic brucellosis. The concept that the endogenous produc-
tion of IL-10, a Th2 cytokine that down-regulates IFN-g pro-
duction and/or increases the susceptibility to a number of bac-
terial [33, 34] and parasitic [35, 36] infections, could actively
down-modulate Th1 responses in brucellosis has gained favor
in the murine model of the disease [11]. PBMC from a small
number of patients with both acute and chronic disease pro-
duced IL-10 in response to CP. Therefore, our data do not
support a major role for IL-10 in the CP-specific T cell unre-
sponsiveness observed in chronic brucellosis, at least in the
cohort of patients under study.
The mRNA levels of TGF-b, another immunoregulatory cy-
tokine [37, 38], were not preferentially induced in cells from pa-
tients with chronic brucellosis. Another mechanism that could
be implicated in the hyporesponsiveness observed in chronically
infected patients is the induction of CP-specific anergy due to
deficient costimulatory signals. However, this seemed to be un-
likely, because the expression of CD80, CD86, and CD40 ligand
mRNA in CP-induced PBMC was not significantly different be-
tween groups. However, the expression of other costimulatory
molecules that boost IFN-g and IL-2 production and prolifer-
ation, such as the signaling lymphocytic activation molecule
(SLAM; CD150) [39], CD28 [40], and the inducible costimulator
[41], were not investigated. Recently, SLAM expression was cor-
related with the polarization of the cellular immune response
against the intracellular pathogen Mycobacterium leprae [42].
Studies are currently underway in our laboratory to determine
the role of these costimulatory molecules in the polarization of
the cellular immune response in human brucellosis. It is also
possible that the differences observed in the cellular responsive-
ness against CP were due to differences in the size of the bacterial
inoculum or in particular features of the infecting species that
could influence the immune response.
Evidence obtained in our laboratory suggests that many in-
ternal antigens are common to all Brucella species [18–20].
Therefore, it seems difficult to attribute the differences in cel-
lular anti-CP responses to antigenic differences among infecting
species. Nevertheless, the cellular response could be influenced
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nately, because of the few positive cultures in our cohort, we
cannot draw any conclusion on this issue.
The differences in the T cell responses are puzzling, and it
is difficult to know whether a change in the pattern of cytokines
occurs at some point during the disease or whether these dif-
ferences arise from the beginning of the disease. Nevertheless,
although it is difficult to establish the pathogenic implications
of this immunologic alteration, we hypothesize that a down-
regulation of the Th1 response could be implicated in the in-
tracellular survival of the bacterium during the chronic phase
of the disease.
Bertotto et al. [43] described a dramatic increase in the num-
ber of activated gd T lymphocytes in patients with acute B.
melitensis infection. The same study showed that the expansion
of these cells (which can be stimulated by Brucella antigens to
proliferate and rapidly secrete large amounts of IFN-g and
tumor necrosis factor–a [44]) was greatly diminished during
convalescence. The preferential Th1-type cytokine secretion in
patients with acute brucellosis observed in our study could be
due to a selective overexpansion of IFN-g–producing gdT cells,
followed by a decrease of these cells during the chronic phase
of the disease. A follow-up study on acute patients would help
address this question.
Moreno-Lafont et al. [13] demonstrated that PBMC from
chronically ill patients with brucellosis proliferated in response
to a sonicated bacterial suspension rich in internal antigens,
whereas cells from patients with acute brucellosis did not. Al-
though this may appear to contradict our findings, their results
were obtained with an antigenic preparation that contained
bacterial LPS and DNA and, therefore, the inherent ability of
these contaminants to induce cellular proliferation could have
masked the protein-specific immune response. Persons with
acute brucellosis have diminished proliferative responses [45]
and defective IFN-g production [46]. However, this hypore-
sponsiveness was not specific, because PBMC were stimulated
with the polyclonal mitogen PHA. Of note, the differences in
all of the responses we investigated (cell proliferation, cytokine
mRNA transcription, and protein production) are CP-specific,
since there was no significant difference in these responses from
subjects when PBMC were stimulated with the mitogen PHA
or with the nonbrucellar antigen PPD.
Although a T cell dichotomy could be observed when patient
PBMC were stimulated with CP, cells from only 2 patients
responded to rBLS in vitro. However, most patients in our study
developed anti-rBLS antibodies (data not shown). rBLS is pres-
ent in the CP antigenic preparation [21]. Therefore, our results
suggest that this antigen displays immunodominant B cell epi-
topes rather than T cell epitopes. The lack of T cell response
against rBLS is not restricted to human infection, since dogs
and mice infected with Brucella species show a marked T cell
hyporesponsiveness against rBLS in the presence of high titers
of specific antibodies (authors’ unpublished data).
Finally, our findings demonstrate that, during human Bru-
cella infection, there is a polarization of the T cell response
against cytoplasmic antigens. This polarized response seems to
be related to the patient’s clinical status. Although in vitro
findings do not necessarily mirror the in vivo situation, our
results indicate that patients with acute brucellosis display a
Th1-type response with cell proliferation and production of
IFN-g and IL-2, whereas patients with the chronic form of the
disease do not. The results also suggest that the CP antigen
could be a useful tool for investigation of antigen-specific T
cell responses in different host. This antigen has a unique char-
acteristic of representing a pool of cytoplasmic proteins com-
mon to all Brucella species, free of the most common contam-
inant of all Brucella antigenic preparation, LPS.
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